Research And Growth

Clinical Research for Existing Products

We are encouraged by the number of patients and families supported by our products and services. It motivates us to continue to seek ways to improve the patient and provider experience with these products and to deliver our therapies to more people who could benefit from them.

Makena® (hydroxyprogesterone caproate injection)

In collaboration with research physicians, we are conducting a large clinical trial that will add to the body of knowledge provided by the NICHD MFMU Network study of hydroxyprogesterone caproate (HPC) injection (Meis NEJM 2003), now available as FDA-approved Makena. To date, the company has enrolled more than 1,100 participants in the study.1,3

We are also developing a potential subcutaneous autoinjector, which, if successfully developed and approved, could improve the patient and provider experience with our product.

Feraheme® (ferumoxytol) injection for intravenous (IV) use

As part of our ongoing commitment to identify and address unmet patient needs, we recently commenced a head-to-head Phase 3 clinical trial to evaluate Feraheme in additional patients.2,3

Please see Feraheme important safety information and full prescribing information.

 

References: 1. AMAG Pharmaceuticals, Inc.; Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery (PROLONG). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 May 05]. Available from: https://clinicaltrials.gov/show/NCT01004029 NLM Identifier: NCT01004029. 2. AMAG Pharmaceuticals, Inc.; A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) (FIRM). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 May 05]. Available from: https://clinicaltrials.gov/ct2/show/NCT02694978 NLM Identifier: NCT02694978. 3. Data on file, AMAG Pharmaceuticals, Inc.